Pre-made Girentuximab benchmark antibody ( Whole mAb Radiolabelled, anti-CA9/CA-IX therapeutic antibody, Anti-CAIX/MN Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).[1] CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-245-1mg	1mg	Inquiry
GMP-Bios-ab-245-10mg	10mg	Inquiry
GMP-Bios-ab-245-100mg	100mg	Inquiry
GMP-Bios-ab-245-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Girentuximab biosimilar, Whole mAb Radiolabelled, Anti-CA9/CA-IX Antibody: Anti-CAIX/MN therapeutic antibody
INN Name	Girentuximab
Target	CA-IX
Format	Whole mAb Radiolabelled
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Centocor Inc;Heidelberg Pharma AG
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Renal cancer
Development Tech	na